Mineral Bone Disease in Chronic Kidney Disease Patients (CKD-MBD) and its Associated Factors at Muhimbili National Hospital in Dar as Salaam, Tanzania: A Cross-sectional Study
Asian Journal of Research in Nephrology,
Background: Mineral bone disease in chronic kidney disease patients is associated with high morbidity and mortality, and it has been reported to start early in the course of the disease and worsen as the kidney damage progresses. However, the prevalence and factors associated with mineral bone disease in chronic kidney disease patients in our setting has not been established, so we aimed to determine the prevalence and factors associated with mineral bone disease among patients with chronic kidney disease at a tertiary Muhimbili National Hospital in Dar es salaam, Tanzania so as to help physicians recognize the patients at risk, diagnose the problem and prevent complications sooner.
Methods: This was a hospital based cross-sectional study involving adult patients with chronic kidney disease attending renal unit Muhimbili National Hospital, a tertiary referral center in Dar es Salaam, Tanzania. In this study, CKD-MBD was defined basing on the abnormality of serum calcium, phosphate or parathyroid hormone level. Data analysis was done using the SPSS version 23.0 software.
Results: A total of 300 participants with chronic kidney disease stage 3 and above were included in this study. Majority were male, 198 (66.0%), with a mean age of 53 years. The prevalence of mineral bone disease was found to be 75.0%. The most common form of mineral bone disease was hyperparathyroidism 196 (87.1%), followed by hypocalcemia 174 (77.3%) and hyperphosphatemia 82 (36.4%), which was the least common.
Factors which were found to be significantly associated with CKD-MBD were the use of calcium supplements, use of phosphate binders, being on dialysis, a calcium rich diet and a low phosphate diet.
Conclusion: Mineral bone diseases are common in patients with CKD at Muhimbili National Hospital. Patients with CKD should undergo serial assessment of phosphate, calcium and parathyroid hormone level, considered together, so as to diagnose mineral bone disease early and treat those patients who will be found to have persistently or prolonged abnormalities in these bone mineral biomarkers.
- Mineral bone disease
- chronic kidney disease
How to Cite
Sanusi AA, Arogundade FA, Oladigbo M, Ogini LM, Akinsola A. Prevalence and pattern of renal bone disease in end stage renal disease patients in Ile-Ife, Nigeria. West African journal of medicine.2010;29(2).
Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases. 2003;42:1-201.
Pei Y, Hercz G, Greenwood C, Serge G, Manuel A, Saiphoo C, Fenton S, Sherrard D. Risk factors for renal osteodystrophy: a multivariant analysis. Journal of Bone and Mineral Research. 1995;10(1):149-56.
Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus and calcium-phosphorus product. American journal of nephrology. 2003;23(6):369- 79.
Pei Y, Hercz G. Low turnover bone disease in dialysis patients. In Seminars in Dialysis. Oxford, UK: Blackwell Publishing Ltd. 1996;9(4):327-331.
Malluche HH, Ritz E, Lange HP, Kutschera J, Hodgson M, Seiffert U, Schoeppe W. Bone histology in incipient and advanced renal failure. Kidney international. 1976 9(4):355-62.
de Francisco AL. Secondary hyperparathyroidism: review of the disease and its management. Clinical therapeutics. 2004;26(12):1976-93.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement. 2009;113:S1.
Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4(5893):643-6.
Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE, Beck G, Modification of Diet in Renal Disease Study Group. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney international. 1997;51(6):1908-19.
Younes NA, Wahbeh A, Mahafzah W, Ailabouni W, Al-Mansour M, Hamzah Y, Sroujieh AS. The spectrum of bone disease in Jordanian hemodialysis patients. Saudi medical journal. 2006;27(5):667.
Boner G, Olah AJ, Weiss A, Seelenfreud MZ, Rosenfeld JB. Renal osteodystrophy in end-stage renal failure patients in Israel.Israel journal of medical sciences. 1983;19(7):608-13.
Jaros A, Zadrazil J, Konecny K, Kosatikova Z, Zahalkova J, Vrublosky P, Krejci K. Single photon bone densitometry in hemodialysis patients. Biomedical papers; 1999.
Abdu A, Abdu A, Arogundade FA. Prevalence and pattern of CKD-MBD among hemodialysis patients in Kano, Northwest Nigeria. Annals of African Medicine. 2019;18(4):191.
Mugera AN. Prevalence and patterns of hyperparathyroidism and mineral bone disease in patients with chronic kidney disease at Kenyatta National Hospital. University of Nairobi; 2013.
Ghosh B, Brojen T, Banerjee S, Singh N, Singh S, Sharma OP, Prakash J. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study. Indian journal of nephrology. 2012;22(4):285.
Jat JA, Mal P, Kumar D. Renal Osteodystrophy in End Stage Renal Failure Patients on Maintenance Haemodialysis. J Clin Exp Nephrol. 2016; 1:25.
Seck SM, Dahaba M, Ka EF, Cisse MM, Gueye S, Tal AO. Mineral and bone disease in black african hemodialysis patients: a report from senegal. Nephro-urology monthly. 2012;4(4):613.
Buargub MA, Nabulsi MF, Shafeh TA. Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients. Saudi Journal of Kidney Diseases and Transplantation. 2006;17(3):401.
Abstract View: 231 times
PDF Download: 94 times